Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SYN-020

Other · developed by Theriva Biologics

Phase 1 Most advanced trial (none active)
TOVX Developer
1 Registered trials

What is SYN-020?

SYN-020 is an oral formulation of intestinal alkaline phosphatase, supplied as enteric-coated, delayed-release pellets in a capsule. It is being studied in radiation enteritis, a bowel injury caused by radiation therapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Intestinal Alkaline Phosphatase
Drug type
Other
Therapy area
Gastroenterology, Oncology
Developer
Theriva Biologics, Inc. (TOVX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
B5JZP72H0D

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04815993 Phase 1 Enteritis Caused by Radiation (Disorder) Completed TOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Enteritis Caused by Radiation (Disorder)

More from Theriva Biologics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TOVX page.

Follow TOVX, the company behind SYN-020

See TOVX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TOVX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.